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Abstract
We analyzed the bacterial communities of the nasopharynx in 40 SARS-CoV-2 infected and uninfected patients. All
infected patients had a mild COVID-19 disease. We did not find statistically significant differences in either bacterial
richness and diversity or composition. These findings suggest a nasopharyngeal microbiota at least early resilient to
SARS-CoV-2 infection.
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Introduction
The human upper respiratory tract is the major portal of
entry for infectious droplet or aerosol-transmitted micro-
organisms, including the 2019 emerged severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2) [1].
Consistent with an ongoing rise in the number of corona-
virus disease 2019 (COVID-19) cases worldwide, the up-
dated World Health Organization estimates on 29 April
2020 reported 3,023,788 confirmed cases, including 208,
112 deaths, over time (https://covid19.who.int/). Because
of apparently absent cross-protective immunity from re-
lated viral infections, SARS-CoV-2 transmissibility is high,
hence facilitating widespread person-to-person transmis-
sion [2]. Both asymptomatic and symptomatic patients
may transmit the virus [3], consistent with similar viral
loads detected in the nasal (sampled from the nasophar-
ynx) and throat swabs from both patients [4].
As with influenza virus, respiratory samples provide
the greatest yield of SARS-CoV-2 nucleic acid shedding
[4, 5]. In one study analyzing nine patients with mild
courses of COVID-19, swab samples taken during the
first week of symptoms displayed high loads and suc-
cessful isolation of the virus and, importantly, the pres-
ence of viral replicative RNA intermediates confirmed
the active replication of SARS-CoV-2 in the throat [5].
The virus uses the host receptor angiotensin-converting
enzyme 2 (ACE2), predominantly expressed in the lung,
to interact with its spike protein [6]. This interaction
would be responsible of the extension of tropism to mul-
tiple tissues [7], which include the throat tissue with
anyhow low ACE2 expression [5], following a fusion ac-
tivity gain of SARS-CoV-2 spike protein at the S1-S2
junction that is not present in SARS-CoV [8].
Unlike influenza virus [9–12], no studies have explored
the relationship between SARS-CoV-2 infection and the
bacterial community (also referred to as microbiota)
within the nasopharynx. Therefore, we investigated
whether the presence of the virus in the nasopharynx
might reflect alterations of the resident microbiota by
comparing the bacterial communities of SARS-CoV-2
infected and uninfected patients.
Methods
We collected nasopharynx samples from patients who
were (n = 18) or were not (n = 22) diagnosed with
COVID-19 based on the SARS-CoV-2 RNA detection
using a real-time reverse transcriptase-polymerase chain
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reaction (RT-PCR) assay [13]. This study received appro-
priate ethical review committee approval, with a waiver
of informed consent.
Patients with samples collected based on the clinical
COVID-19 suspicion (i.e., who presented symptoms of
acute respiratory infection in the emergency department
of the Fondazione Policlinico Universitario A. Gemelli
(FPG) IRCCS Hospital of Rome, Rome, Italy) [14] from
March 6 through March 9, 2020, were included. Naso-
pharyngeal swabs were tested for RT-PCR based
COVID-19 diagnosis [13] using the Korean Ministry of
Food and Drug Safety approved Allplex 2019-nCoV
assay (Arrow Diagnostics S.r.l., Genova, Italy). The same
samples were used to profile the nasopharyngeal micro-
biota in all 40 patients concomitantly.
Genomic DNA was extracted using the QIAGEN EZ1
Advanced XL system and the V5–V6 hypervariable region
of the bacterial 16S rRNA gene was sequenced using an
Illumina MiSeq V2 chemistry (2 × 250 bp) as described
[11]. Sequencing data were processed for alignment and
quality filtering in QIIME2 v2019.1 [15, 16], and represen-
tative amplicon sequence variants were obtained by the
DADA2 algorithm [17] available at https://doi.org/10.
1038/s41587-019-0209-9. Samples were rarefied to the
minimum number of sequence reads obtained totally
(range, 107,933–165,427) to perform subsequent analyses.
Taxonomic annotation was performed using both VSEA
RCH [18] and SILVA database v132 [19]. Statistical tests,
including Wilcoxon signed rank test and permutational
analysis of variance (PERMANOVA) were performed in R
software (R Foundation for Statistical Computing, version
3.6.0).
No patients developed pneumonia as documented in
the absence of significant abnormalities (i.e., multifocal
Fig. 1 Diversity (a), clustering (b), and taxa abundances (c) of nasopharynx bacterial communities from SARS-CoV-2 positive or negative patients,
respectively. In (a) indexes to measure the diversity within samples are shown, in (b) dissimilarity between samples is calculated as the Bray-Curtis
or the Jaccard distance, and in (c) taxa represent 20 relatively most abundant genera within the five phyla that compose the nasopharynx
bacterial community
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ground-glass opacities) on chest computed tomography
(CT) images.
Results
The microbiota of the nasopharynx was not different in
patients positive for SARS-CoV-2 RNA compared to the
microbiota of patients negative for SARS-CoV-2 RNA
(Fig. 1). No significant differences between the patient
groups in either bacterial richness and diversity (ob-
served species, Shannon index, and inverse Simpson
index were assessed; P > 0.05 by Wilcoxon signed rank
test) or composition (no samples clustering within each
group, as visualized by multidimensional scaling; P >
0.05 by PERMANOVA) was noticed.
We analyzed the relative abundance of bacterial taxa
most represented in both patient groups and did not ob-
serve significant differences between the groups. Most
sequences in all samples (98% in both SARS-CoV-2 in-
fected and uninfected patients) belonged to five phyla,
namely Firmicutes (42 and 51%, respectively), Bacteroi-
detes (25 and 20%, respectively), Proteobacteria (18 and
16%, respectively), Actinobacteria (8 and 6%, respect-
ively), and Fusobacteria (5 and 5%, respectively). These
findings were consistent with the high similarity shared
by the bacterial communities in both SARS-CoV-2 in-
fected and uninfected patients.
Discussion
In this study, SARS-CoV-2 infection was not associated
with a different profile of the nasopharynx bacterial
community analyzed at COVID-19 diagnosis, which is
when the patients had a mild disease. This suggests that
no microbiota compositional alterations occurred in re-
sponse to SARS-CoV-2 or that SARS-CoV-2 was unable
to induce these alterations in our patients. Both sugges-
tions lend support to a nasopharyngeal microbiota at
least early resilient to SARS-CoV-2 infection.
As nasopharyngeal swabs can be a reasonable proxy
for lung samples [20], resilience of the nasopharynx bac-
terial community would also imply robustness of lung
bacterial community in restricting SARS-CoV-2 growth
or attachment. This would mirror a lack of effect on the
oropharyngeal microbiota in volunteers challenged with
H3N2 influenza virus, many of which developed very
mild disease [12]. Thus, we did not find bacterial taxa
for which relative abundance was significantly higher in
SARS-CoV-2 infected patients. Conversely, taxa such as
Dolosigranulum, Moraxella, Staphylococcus, and Strepto-
coccus (three of which also detected in our study) were
found to be enriched in the nasopharynx microbiota of
H3N2 influenza virus infected patients compared to
healthy control individuals [11].
In one study that analyzed elderly pneumonia patients
in comparison with healthy elderly [10], oropharyngeal
microbiota profiles differed significantly between the
groups, with three of them being significantly associated
with pneumonia. Therefore, it is surprising that no pub-
lished studies until now reported association between
upper respiratory tract microbiota and COVID-19, espe-
cially in severe disease cases. Here, we studied COVID-
19 patients at a time when (mild) symptoms were typical
of upper respiratory tract infection and were not affect-
ing the lungs. Consistently, no patients had multifocal
ground-glass opacities on chest CT [21], as mentioned
above.
The limitations of this study are that SARS-CoV-2 in-
fections were defined by RT-PCR positivity, with no cul-
ture results, likely leading to include infections with low
infectiousness and the number of analyzed samples was
small. Although RT-PCR performed on a nasopharyn-
geal swab remains the reference diagnostic test [13], pa-
tients with negative RT-PCR results could be highly
probable COVID-19 cases based on positive chest CT
findings [22]. We did not use chest CT to screen for
SARS-CoV-2 infection [23] because of awareness that
CT findings can be absent, especially in patients with
early and/or mild disease [21]. Therefore, we cannot ex-
clude the possibility that false negative RT-PCR results
have biased the grouping of patients in our study. Fur-
ther investigation of SARS-CoV-2 infected patients with
detailed viral shedding data and sequential respiratory
samples is warranted.
Acknowledgments
We thank Franziska Lohmeyer, PhD (Scientific Direction, Fondazione Policlinico
Universitario A. Gemelli IRCCS, Rome, Italy) for English revision of the manuscript, and
clinical staff members in Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome,
Italy for collection of samples. None of these individuals received compensation for
their contributions.
Authors’ Contributions
FDM and MS had full access to all of the data in the study and take
responsibility for the integrity of the data and the accuracy of the data analysis.
FDM, BP and MS conceived and designed the experiments. FDM, BP, FRP and
MS acquired, analyzed and interpreted the data. FDM, BP and MS drafted the
manuscript. PC, AG and MS critically revised the manuscript for important
intellectual concept. FDM and FRP performed statistical analyses. FDM and BP
contributed equally to this manuscript.
Funding
This work was funded by donations from Reale Group and Fondazione
Valentino Garavani & Giancarlo Giammetti to support the COVID-19 Research
in our Institution. The funders had no role in the design and conduct of the
study; collection, management, analysis, and interpretation of the data; prep-
aration, review, or approval of the manuscript; and decision to submit the
manuscript for publication.
Availability of Data and Materials
All data analyzed in this study are available from the corresponding author
on request.
Ethics Approval and Consent to Participate
This study was approved by the Ethics Committee of the FPG (approval
number 17057/20), with a waiver of informed consent.




The authors declared that they have no competing interests.
Author details
1Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione
Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome,
Italy. 2Dipartimento di Scienze Gastroenterologiche, Endocrino-Metaboliche e
Nefro-Urologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS,
Rome, Italy.
Received: 6 May 2020 Accepted: 16 July 2020
References
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with
pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.
2. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated
with the 2019 novel coronavirus indicating person-to-person transmission: a
study of a family cluster. Lancet. 2020;395:514–23.
3. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the
rapid dissemination of novel coronavirus (SARS-CoV2). Science. 2020;368:
489–93.
4. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory
specimens of infected patients. N Engl J Med. 2020;382:1177–9.
5. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of
hospitalized patients with COVID-2019. Nature. 2020;581:465–9.
6. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry
depends on ACE2 and TMPRSS2 and is blocked by a clinically proven
protease inhibitor. Cell 2020; 181:271–280.e8.
7. Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly
expressed in nasal epithelial cells together with innate immune genes. Nat
Med. 2020;26:681–7.
8. Letko M, Marzi A, Munster V. Functional assessment of cell entry and
receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat
Microbiol. 2020;5:562–9.
9. Greninger AL, Chen EC, Sittler T, et al. A metagenomic analysis of pandemic
influenza a (2009 H1N1) infection in patients from North America. PLoS
One. 2010;5:e13381.
10. Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory viral infection-
induced microbiome alterations and secondary bacterial pneumonia. Front
Immunol. 2018;9:2640.
11. Ding T, Song T. Zhou B, et al. Microbial composition of the human
nasopharynx varies according to influenza virus type and vaccination status
mBio. 2019;10:e01296–19.
12. Ramos-Sevillano E, Wade WG, Mann A, et al. The effect of influenza virus on
the human oropharyngeal microbiome. Clin Infect Dis. 2019;68:1993–2002.
13. WHO. Laboratory testing for coronavirus disease (COVID-19) in suspected




14. WHO. Global surveillance for COVID-19 caused by human infection with
COVID-19 virus. Interim guidance. Geneva, World Health Organization, 2020.
Available at: https://www.who.int/docs/default-source/coronaviruse/global-
surveillance-for-covid-v-19-final200321-rev.pdf. Accessed 26 April 2020.
15. Mohsen A, Park J, Chen YA, Kawashima H, Mizuguchi K. Impact of quality
trimming on the efficiency of reads joining and diversity analysis of Illumina
paired-end reads in the context of QIIME1 and QIIME2 microbiome analysis
frameworks. BMC Bioinformatics. 2019;20:581.
16. Hall M, Beiko RG. 16S rRNA gene analysis with QIIME2. Methods Mol Biol.
1849;2018:113–29.
17. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP.
DADA2: high-resolution sample inference from Illumina amplicon data. Nat
Methods. 2016;13:581–3.
18. Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open
source tool for metagenomics. PeerJ. 2016;4:e2584.
19. Quast C, Pruesse E, Yilmaz P, et al. The SILVA ribosomal RNA gene database
project: improved data processing and web-based tools. Nucleic Acids Res.
2013;41:D590–6.
20. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial
populations in the healthy human respiratory tract. Am J Respir Crit Care
Med. 2011;184:957–63.
21. El Homsi M, Chung M, Bernheim A, et al. Review of chest CT manifestations
of COVID-19 infection. Eur J Radiol Open. 2020;7:100239.
22. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in
coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases.
Radiology. 2020;200642.
23. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-
19): rRT-PCR or CT? Eur J Radiol. 2020;126:108961.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
De Maio et al. Biological Procedures Online           (2020) 22:18 Page 4 of 4
